News
Absolute increase in Kawasaki CV risk remains small in long-term follow-up
- Author:
- Ted Bosworth
Relative to controls, the increased long-term cardiovascular risk of patients with Kawasaki disease is small in most patients.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Cha_Jung_Joon_KOREA_web.jpg)
Delays in NSTEMI hospitalization linked to lower survival
- Author:
- Ted Bosworth
After onset of non-STEMI symptoms, delays in hospitalization are linked to poorer long-term outcomes.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/aspirin_web.jpg)
Daily aspirin linked to increased risk of heart failure
- Author:
- Ted Bosworth
Daily aspirin may need to be reconsidered in those at risk of heart failure, based on evidence of an association.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Bhatt_Deepak_L_Boston_web.jpg)
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
- Author:
- Ted Bosworth
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Perin_Emerson_C_HOUSTON_web.jpg)
DREAM-HF: Negative stem cell trial in heart failure may still offer promise
- Author:
- Ted Bosworth
Despite zero evidence of benefit on the primary endpoint, stem cell transplant is still promising in heart failure.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Van_Spell_Harriette_GC_CAN_web.jpg)
EHRs have no impact on inpatient heart failure clinical choices or outcomes
- Author:
- Ted Bosworth
Relative to usual care, prognostic information at the bedside provided no advantage for heart failure care.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/lariat3_web.jpg)
No advantage shown for LAA ligation as adjunct to pulmonary vein isolation
- Author:
- Ted Bosworth
For AFib control, left atrial appendage ligation is not additive to pulmonary vein ventral isolation at 12 months.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/November-2018/Blood_pressure_PA_web.jpg)
BP Track: Blood pressure control rates dropped during pandemic
- Author:
- Ted Bosworth
Data culled from 24 health systems showed lower rates of blood pressure control during the COVID-19 pandemic.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lakkireddy_Dhanunjaya_KAN_web.jpg)
Direct comparison shows differing strengths for left atrial closure devices
- Author:
- Ted Bosworth
For left atrial appendage closure, differences are found between the Amplatzer Amulet and the Watchman FLX in randomized trials.
News
At 5 years, iFR found as effective and safe as FFR for guiding PCI intervention
- Author:
- Ted Bosworth
Five-year data reinforce prior finding: iFR and FFR are comparably effective and safe for guiding revascularization.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Gupta_Sanjay_NY_web.jpg)
Practicing telepsychiatry: Include backup plans, ground rules
- Author:
- Ted Bosworth
Ideally, telepsychiatry will function much like an inpatient office visit, but the dynamics differ – as do the things that can go wrong.
News
Short DAPT course beneficial after PCI in ‘bi-risk’ patients
- Author:
- Ted Bosworth
MASTER DAPT subgroup analysis supports short antiplatelet course in cases of high bleeding and ischemic risk.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/sugar_cubes_web.jpg)
SUGAR trial finds superior stent for those with diabetes and CAD
- Author:
- Ted Bosworth
In noninferiority trial, the Cre8 EVO stent was associated with fewer target lesion failures than the Resolute Onyx at 1 year in the setting of...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Bhatt_Deepak_L_Boston_web.jpg)
Renal denervation remains only promising, per latest meta-analysis
- Author:
- Ted Bosworth
A fairly large body of evidence showing safety and efficacy for renal denervation is not enough for an indication.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Nasrallah_Henry_OHIO_web2.jpg)
FDA not recognizing efficacy of psychopharmacologic therapies
- Author:
- Ted Bosworth
If this reorientation is going to lead to the broad indications the newer drugs likely deserve, “we have to move the FDA along,” said Dr. Stephen...